All In Biotech

Drug Trial Radar · NCT06008756

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 14,550 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

14,550

Planned (sponsor's estimate)

Start

Oct 9, 2023

Primary completion

Nov 29, 2029

Study completion Nov 29, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Aug 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of enlicitide decanoate compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial revascularization.

Conditions

  • Arteriosclerosis
  • Hypercholesterolaemia

Interventions

  • Enlicitide DecanoateDrug

    Enlicitide Decanoate 20 mg tablet taken by mouth.

  • PlaceboDrug

    Placebo tablet matched to enlicitide decanoate taken by mouth.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blinded Period: Time to First Occurrence of Coronary Heart Disease (CHD) Death-Based Major Adverse Cardiovascular Events (MACE)-PlusTime frame: From date of randomization until the date of first occurrence of CHD death-based MACE-plus, assessed up to approximately 6 years

Locations

669 sites in 29 countries. Site status is shown where the registry gives one.

  • Advanced Cardiovascular - Alexander City ( Site 0156)

    Alexander City, Alabama

  • Central Research Associates ( Site 0118)

    Birmingham, Alabama

  • St. Vincent's Birmingham Hospital ( Site 0181)

    Birmingham, Alabama

  • Central Alabama Research ( Site 0109)

    Birmingham, Alabama

  • Alliance for Multispecialty Research, LLC ( Site 0076)

    Daphne, Alabama

  • G&L Research ( Site 0042)

    Foley, Alabama

  • NextStage Clinical Research - Phoenix - (01) ( Site 0191)

    Glendale, Arizona

  • Synexus Clinical Research US, Inc.-Synexus Clinical Research US, Inc - Central Phoenix ( Site 0066)

    Phoenix, Arizona

  • Medical Investigations Inc. ( Site 0188)

    Little Rock, Arkansas

  • National Heart Institute-Research ( Site 0077)

    Beverly Hills, California

  • UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130)

    La Jolla, California

  • Chemidox Clinical Trials ( Site 0145)

    Lancaster, California

  • Velocity Clinical Research, Westlake ( Site 0039)

    Los Angeles, California

  • Carbon Health - Pasadena ( Site 0149)

    Pasadena, California

  • Carbon Health - San Mateo - Hillsdale Mall ( Site 0151)

    San Mateo, California

  • America Clinical Trials-Research Dept ( Site 0104)

    Tarzana, California

  • Premiere Medical Center ( Site 0093)

    Toluca Lake, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 0058)

    Torrance, California

  • University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 0146)

    Aurora, Colorado

  • South Denver Cardiology Associates ( Site 0167)

    Littleton, Colorado

  • Cardiology Associates of Fairfield County, P.C. ( Site 0159)

    Stamford, Connecticut

  • Chase Medical Research, LLC ( Site 0046)

    Waterbury, Connecticut

  • Emerson Clinical Research Institute ( Site 0143)

    Washington D.C., District of Columbia

  • Excel Medical Clinical Trials ( Site 0052)

    Boca Raton, Florida

  • Advanced Pharma Research ( Site 0040)

    Cutler Bay, Florida

  • Alliance for Multispecialty Research, LLC ( Site 0083)

    Fort Myers, Florida

  • Westside Center for Clinical Research ( Site 0049)

    Jacksonville, Florida

  • University of Florida - Jacksonville ( Site 0166)

    Jacksonville, Florida

  • East Coast Institute for Research, LLC ( Site 0031)

    Jacksonville, Florida

  • Jacksonville Center for Clinical Research ( Site 0048)

    Jacksonville, Florida

  • East Coast Institute for Research ( Site 0034)

    Lake City, Florida

  • Columbus Clinical Services ( Site 0026)

    Miami, Florida

  • Miami Cardiac & Vascular Institute-Ambulatory Research ( Site 0059)

    Miami, Florida

  • Inpatient Research Clinic ( Site 0041)

    Miami Lakes, Florida

  • Eminat ( Site 0082)

    Miramar, Florida

  • Ocala Research Institute - Ocala - Southwest 20th Place ( Site 0079)

    Ocala, Florida

  • Progressive Medical Research ( Site 0045)

    Port Orange, Florida

  • St Johns Center for Clinical Research ( Site 0016)

    Saint Augustine, Florida

  • Clinical Site Partners LLC, dba CSP Orlando ( Site 0067)

    Winter Park, Florida

  • The Jones Center Clinical Research ( Site 0032)

    Macon, Georgia

Showing 40 of 669 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.